Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1010-1013

  Taranger, John ^a,c   Trollfors, Birger ^a   Lagergård, Teresa ^a   Sundh, Valter ^a   Bryla, Dolores A ^b   Schneerson, Rachel ^b   Robbins, John B ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Göteborg Pertussis Vacc Trial ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE; VIRULENCE FACTOR;

ANTIBODY DETECTION; ARTICLE; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; INFANT; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TIME FACTORS; VACCINATION; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0034085715     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315318     Document Type: Article

References (31)

1. 1. Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis J 1984;3:467-86.
2. 2. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996;334:391-2.
3. 3. Ad hoc group for the study of pertussis vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1988;1:955-60.
4. 4. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 1995;333:1045-50.
5. 5. Zackrisson G, Taranger J, Trollfors B. History of whooping cough in non-vaccinated Swedish children related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr 1990;116:190-4.
6. 6. Granström M, Granström G. Serological correlates in whooping cough. Vaccine 1993;11:445-8.
7. 7. Robbins JB, Pittman M, Trollfors B, Lagergård T, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 1993;12:795-807.
8. 8. Siber GR. Methods for estimating serological correlates of protection. Dev Biol Stand 1997;89:283-96.
9. 9. Taranger J, Trollfors B, Lagergård T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997;16:180-4.
10. 10. Krantz I, Taranger J, Trollfors B. Estimating incidence of whooping cough over time: a cross-sectional recall study of four Swedish birth cohorts. Int J Epidemiol 1989;18:959-63.
11. 11. Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol 1977;6:303-9.
12. 12. WHO meeting on case definitions of pertussis, Geneva, 10-11 January. Geneva: World Health Organization MIM/EPI/PERT/91.1, 1991.
13. 13. Mink CAM, Cherry JD, Christenson P, et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464-71.
14. 14. Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infection in adolescents. Am J Dis Child 1993; 147:575-7.
15. 15. Reizenstein E, Hallander HO, Blackwelder WC, Kühn I, Ljungman M, Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995;183:279-90.
16. 16. Trollfors B, Taranger J, Lagergård T, et al. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J Pediatr 1997;130:532-6.
17. 17. Medical Research Council. The prevention of whooping-cough by vaccination. Br Med J 1951;i:1463-71.
18. 18. Broome CV, Preblud SR, Bruner B, et al. Epidemiology of pertussis, Atlanta, 1977. J Pediatr 1981;98:362-7.
19. 19. Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am J Dis Child 1992;146:167-72.
20. 20. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998;16:1907-16.
21. 21. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998;16: 1901-6.
22. 22. Lagergård T, Trollfors B, Claesson B, Karlberg J, Taranger J. Determination of neutralizing antibodies and specific immunoglobulin isotype levels in infants after vaccination against diphtheria. Eur J Clin Microbiol Infect Dis 1992;11:341-5.
23. 23. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Stand 1997;89:275-8.
24. 24. Ramsay ME, Corbel MJ, Redhead K, Ashworih LAE, Begg NT. Persistence of antibody after accelerated immunisation with diphtheria-tetanus-pertussis vaccine. Br Med J 1991;302:1489-91.
25. 25. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100.
26. 26. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973;7:103-10.
27. 27. Santosham M, Reid R, Ambrosino DM, et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 1987;317:3-929.
28. 28. Edsall G. Immunization of adults against diphtheria and tetanus. Am J Public Health 1952;42:393-400.
29. 29. Ipsen J. Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 1946;54:325-447.
30. 30. Scheibel I, Tulinius S, Rasch G, Bojlen K, Borg Petersen C. Acta Pathol Microbiol Scand 1948;25:319-50.
31. 31. Orenstein OA, Weisfeld JS, Halsey NA. Diphtheria and tetanus toxoids and pertussis vaccine combined. Washington, DC: Pan American Health Organization, World Health Organization, 1983:30-51. Publication 451.